iCliniq Logo
HomeHealth articlesGeneral Medicinerheumatoid arthritis
Drug and Supplements

JAK Inhibitors in Treating Rheumatoid Arthritis

Verified data
0

5 min read

Share

Outline

Doctors mainly suggest JAK or Janus kinase inhibitors for patients with rheumatoid arthritis to ease their symptoms. Read this article to learn more.

Written byDr. Porwal Himanshi Avadheshkumar

Medically reviewed byDr. Mohammad Rajja

Published At August 2, 2022
Reviewed AtAugust 21, 2025
JAK Inhibitors in Treating Rheumatoid Arthritis

What Are JAK Inhibitors?

JAK inhibitors drugs or Janus kinase inhibitors are used to treat joint pain and swelling in patients suffering from rheumatoid arthritis. They are a new class of medications developed by researchers for patients whose rheumatoid arthritis is difficult to treat. They belong to the class of disease-modifying antirheumatic drugs (DMARD). In rheumatoid arthritis, the body’s immune system gets overactive and attacks the healthy cells in the lining of the joints and other organs of the body. JAK drugs work by suppressing the immune response, helping prevent damage to the joints. JAK inhibitors potentially reduce the disease activity in people with rheumatoid arthritis, but the ultimate goal of the treatment is sustained remission.

How Do JAK Inhibitors Work Against Rheumatoid Arthritis?

JAK inhibitors belong to the category of drugs called DMARDs. To date, the Food and Drug Administration (FDA) has approved three JAK inhibitors, which are listed below:

If a patient has been diagnosed with rheumatoid arthritis, his body makes the proteins known as cytokines in excess. These cytokines mediate an inflammatory response in the body tissues. These cytokines bind to the receptors present in the immune cells of the body like a key fits into a lock. When this happens, the body cells receive the message that they need to make more cytokines. This is the point when the JAK inhibitors come into action. They hinder this inflammatory procedure and ease the symptoms of rheumatoid arthritis. These JAK inhibitors directly interfere with the production of cytokines and interrupt their signaling pathways. However, as per the researchers, JAK inhibitors are not effective against all the cytokine molecules and might not provide many benefits to some individuals. They just limit the progression of rheumatoid arthritis rather than removing the root cause of the problem.

What Are the Different JAK Inhibitors?

JAK inhibitors have gained much popularity over the past few years because of their targeted mechanism of action and oral delivery route. However, the biggest dilemma associated with the drug is the risk of herpes zoster infection. The different JAK inhibitors approved by the FDA are listed below:

  • Tofacitinib - It was the first JAK inhibitor that was launched in the market to treat rheumatoid arthritis. Tofacitinib 5 mg was approved by the FDA to be taken twice a day. This drug is effective for people suffering from moderate to severe arthritis who have had an inadequate response or did not benefit from other drugs. The studies have reported that the Tofacitinib and Methotrexate combination is more effective than Tofacitinib alone.
  • Baricitinib - Baricitinib has been specifically approved for the management of active rheumatoid arthritis. It directly inhibits the Janus kinase enzymes involved in the inflammation and symptoms of rheumatoid arthritis. During the clinical studies, it was noted that Barictinib was superior and far better than the other drugs in treating rheumatoid arthritis.
  • Upadacitinib - Upadacitinib has been shown to have a better safety profile than Baricitnib and Tofacitinib. It has to be taken once daily, but the drug demonstrated low disease activity and high remission rates when administered to the patients in the clinical trial.

What Has Been Known About the Efficacy of JAK Inhibitors Against Rheumatoid Arthritis?

The study reports that these drugs have been found to be effective and relatively safe for treating moderate to severe rheumatoid arthritis. Some researchers indicate that JAK inhibitors are more effective than Adalimumab and other drugs of the same class. According to the clinical trials conducted in 2017 and 2019 to evaluate the safety and efficacy of JAK inhibitors, it was discovered that people who took these drugs showed 20 % improvements in the key symptoms of rheumatoid arthritis. This proves that JAK inhibitors are effective for the ones who have not responded well to other treatments. However, more relevant studies and clinical trials are needed to evaluate the safety and efficacy of JAK inhibitors.

What Has Been Known About the Safety of JAK Inhibitors in Rheumatoid Arthritis?

JAK inhibitors are the new drugs that have been launched in the market, so not much is known about the safety of JAK inhibitors. However, the studies suggest that they pose risks similar to other drugs of the same class. The study report published in 2020 concluded that the safety profile of JAK inhibitors is consistent with the other biological drugs used to treat rheumatoid arthritis. JAK inhibitors are basically immunosuppressant drugs associated with an increased risk of severe and opportunistic infections. Some people might develop herpes zoster infection after taking JAK inhibitors. However, a clinical trial reported that the risk of herpes infection in people taking JAK inhibitors is less than in those taking other drugs.

Who Benefits the Maximum From JAK Inhibitors?

Some people might not need JAK inhibitors because older drugs like Adalimumab and Methotrexate help control their symptoms of rheumatoid arthritis. However, the old drugs might not be suitable and efficacious for everyone. It has been noted that 65 % of patients who take DMARDs get relieved from their symptoms. If the person taking the drug belongs to the group of these 65 % people, then DMARDs are definitely of great help. One of the studies noted that more than half of the people who did not see improvements in their symptoms after taking the biological drugs, their symptoms became less severe after taking a JAK inhibitor for three months. The biggest advantage of the JAK inhibitors is that they can be taken orally, unlike the other biologic drugs like Adalimumab that need to be injected into the skin.

What Are the Side Effects of JAK Inhibitors?

As JAK inhibitors interfere with the immune system's functioning, they might leave the patient vulnerable to infectious diseases. In addition, the following side effects have been noted to date:

  • During a clinical trial, it was observed that people who took Tofacitinib presented with severe respiratory diseases like tuberculosis.

  • The risk of herpes zoster also increases after taking JAK inhibitors. However, the drugs have a short half-life, meaning that the patient’s immune system will return to normal after he stops taking them.

  • Some patients might suffer from anemia after taking JAK inhibitors because they directly affect the protein required to make red blood cells in the body.

  • JAK inhibitors can also reduce the white blood cell count.

  • These medications can elevate the cholesterol levels of a person. However, the levels can be brought back to normal by taking statin drugs.

  • Some doctors are concerned that the patient might be at risk of developing cancer because this drug reduces the immune system’s ability to fight the tumor cells.

  • People suffering from cardiac diseases might show the formation of blood clots after taking these drugs.

Medicine experts discourage the administration of Janus kinase (JAK) inhibitors to pregnant or breastfeeding women except when the medical benefits exceed safety risks. Common JAK inhibitor side effects may include an increased risk of infections, headaches, elevated blood pressure, gastrointestinal issues, liver enzyme abnormalities, blood clotting issues, increased cholesterol levels, and changes in blood counts.

JAK inhibitors and Alcohol

Combining JAK inhibitors with alcohol should be approached with caution, especially for individuals taking JAK inhibitors for rheumatoid arthritis. Both JAK inhibitors and alcohol can affect liver function, and when taken together, they may increase the risk of liver damage or abnormalities in liver enzymes. People who take JAK inhibitors for rheumatoid arthritis face impaired immune function because these drugs suppress the immune system along with alcohol, which makes patients more susceptible to infections or affects the effectiveness of their medication. Double pain originates from gastrointestinal irritation, which thereby intensifies the probability of gastric distress as well as nausea. Furthermore, alcohol may intensify some of the common side effects of JAK inhibitors, such as dizziness, headaches, or drowsiness. When using JAK inhibitors to treat rheumatoid arthritis, you should only drink alcohol moderately, yet you need to check with your healthcare provider for thoughts regarding your individual treatment plan.

Are JAK Inhibitors Safe?

JAK inhibitors can be effective for treating conditions like rheumatoid arthritis, but their safety depends on the individual and the specific circumstances. While many people tolerate these medications well, they come with potential risks such as increased susceptibility to infections, liver enzyme abnormalities, cardiovascular issues, blood clotting disorders, gastrointestinal problems, and a possible increased risk of certain cancers with long-term use. JAK inhibitors remain one of the treatment options for autoimmune patients because their benefits typically overcome possible negative results. The safety recommendations include periodic healthcare checks for liver and cholesterol markers along with other health parameters. Your healthcare provider needs to examine the risks against benefits according to personal medical history and specific health requirements.

Conclusion:

The management of rheumatoid arthritis benefits greatly from JAK inhibitors because these drugs directly intervene with immune system functions and prevent the disease from advancing further. JAK inhibitors help patients with extended rheumatoid arthritis who did not succeed with prior treatments or medications. These drugs act as exceptional solutions for such cases. Patients need not worry about the many side effects because their immune system returns to normal after stopping JAK inhibitor usage. Unattended rheumatoid arthritis patients need immediate medical assessment to acquire information about JAK inhibitors and their advantages.

Listen to related tracks in our music library

Frequently Asked Questions

Yes, JAK inhibitors are generally considered safe for rheumatoid arthritis (RA) patients, although, like any medication, they come with potential risks and side effects. These inhibitors target specific enzymes called Janus kinases (JAKs) that play a role in the inflammatory process of RA. By inhibiting JAKs, these drugs help reduce inflammation and alleviate symptoms. However, patients should work closely with their healthcare provider to monitor for adverse effects and ensure proper management while using JAK inhibitors as part of their RA treatment plan.
JAK, or Janus kinase, plays a crucial role in rheumatoid arthritis by contributing to the inflammatory response. In RA, the immune system mistakenly attacks joint tissues, leading to chronic inflammation, pain, and damage. JAKs are involved in signaling pathways that promote inflammation and immune responses. Targeting JAKs with inhibitors helps modulate these pathways, reducing inflammation and relieving rheumatoid arthritis in affected individuals.
The mechanism of action of JAK inhibitors in the context of rheumatoid arthritis involves targeting Janus kinase enzymes, which are integral to the signaling pathways that drive inflammation and immune responses. By inhibiting JAKs, these drugs disrupt the activation of immune cells and release pro-inflammatory molecules, reducing the overall inflammatory cascade and helping alleviate symptoms, thereby slowing the disease progression. JAK inhibitors thus provide a focused approach to dampening the immune system's hyperactivity associated with the disease.
The first JAK inhibitor approved for treating rheumatoid arthritis was tofacitinib. Tofacitinib was a pioneering medication in this class, gaining approval for use in RA in recent years. It targets specific Janus kinase enzymes, thus interfering with the inflammatory pathways that contribute to the progression of rheumatoid arthritis. Tofacitinib's approval marked a significant advancement in the treatment options available to individuals with this condition.
JAK inhibitors and DMARDs (Disease-Modifying Antirheumatic Drugs) have distinct mechanisms of action in treating rheumatoid arthritis. While both aim to control inflammation and slow disease progression, DMARDs have a broader impact on the immune system, affecting various cell types. In contrast, JAK inhibitors specifically target Janus kinase enzymes involved in immune responses and inflammation. This focused approach provides a more targeted therapeutic effect, offering an alternative option for individuals who may not respond well to traditional DMARD treatments.
No, methotrexate is not classified as a JAK inhibitor. Methotrexate is a commonly used DMARD (Disease-Modifying Antirheumatic Drug) in treating rheumatoid arthritis. It works by suppressing the immune system and reducing inflammation, but its mechanism of action is different from that of JAK inhibitors. Methotrexate is often prescribed as a first-line RA treatment and combined with other medications to manage the condition.
Tofacitinib serves as a JAK inhibitor in the treatment of rheumatoid arthritis. It explicitly targets Janus kinase enzymes, which play a pivotal role in the inflammatory processes associated with RA. Tofacitinib helps regulate the immune response, reduce inflammation, and alleviate symptoms by inhibiting these enzymes. Its targeted mechanism of action offers a valuable option for individuals who have not adequately responded to other treatments or are seeking an alternative approach to managing their rheumatoid arthritis.
The mode of operation of tofacitinib in the context of rheumatoid arthritis involves inhibiting Janus kinase enzymes, which are integral to the signaling pathways that drive inflammation and immune responses. By disrupting the activity of these enzymes, tofacitinib helps modulate the exaggerated immune response seen in rheumatoid arthritis, leading to a reduction in inflammation and symptom relief. This targeted approach allows for a more precise intervention in the disease process, offering potential benefits to individuals dealing with the challenges of rheumatoid arthritis.
Medications categorized as JAK inhibitors include Tofacitinib, Baricitinib, and Upadacitinib. These drugs target Janus kinase enzymes, significantly regulating immune responses and inflammation. By inhibiting these enzymes, JAK inhibitors help control the underlying inflammatory processes associated with rheumatoid arthritis, offering a targeted approach to symptom management and disease progression.
Comparing JAK inhibitors to methotrexate, studies have shown that JAK inhibitors can offer effective relief for Rheumatoid Arthritis (RA) symptoms, particularly in individuals who have not responded adequately to methotrexate or other treatments. JAK inhibitors have a targeted mechanism of action, focusing on specific inflammatory pathways. However, the choice between JAK inhibitors and methotrexate depends on individual patient preferences, medical history, and disease severity. Consulting a healthcare provider is essential to determine the most suitable treatment approach for each RA patient.
No, sulfasalazine is not a JAK inhibitor. It is a Disease-Modifying Antirheumatic Drug (DMARD) commonly used to treat rheumatoid arthritis. Sulfasalazine works by reducing inflammation and slowing down the progression of the disease. While it shares the goal of managing rheumatoid arthritis symptoms, its mechanism of action is distinct from that of JAK inhibitors, which specifically target Janus kinase enzymes involved in the inflammatory process.
JAK inhibitors were approved for treating rheumatoid arthritis at different times depending on the specific medication. Tofacitinib was initially approved by the U.S. Food and Drug Administration (FDA) for treating moderate-to-severe rheumatoid arthritis in 2012. Other JAK inhibitors like Baricitinib and Upadacitinib (Rinvoq) followed with their respective approvals in subsequent years. These approvals marked significant advancements in providing targeted therapies for rheumatoid arthritis patients.
Individuals with a history of severe infections, certain cancers, or hypersensitivity to the medication should avoid Tofacitinib. Additionally, those with compromised immune systems or significant liver dysfunction should exercise caution or avoid its use. Patients must discuss their medical history and current health status with a healthcare provider before starting tofacitinib or any other medication to ensure its suitability and safety for their circumstances.
Tofacitinib has been associated with potential liver damage, particularly in cases where higher doses are used or in combination with other medications that affect the liver. Regular monitoring of liver function is essential during Tofacitinib treatment. Patients are advised to promptly report any symptoms of liver dysfunction, such as jaundice, abdominal pain, or dark urine, to their healthcare provider. Close monitoring and adherence to recommended guidelines help mitigate the risk of liver-related issues while using tofacitinib for rheumatoid arthritis.
The risk associated with Tofacitinib usage includes an increased susceptibility to infections due to its impact on the immune system. This risk may vary based on factors such as the dosage and other medical conditions. Patients must be vigilant about any signs of infection, such as fever, cough, or urinary symptoms, and promptly seek medical attention if such symptoms arise during Tofacitinib treatment. Healthcare providers closely monitor patients for infections and adjust treatment plans as needed to ensure the safety and well-being of individuals using this medication for rheumatoid arthritis.
The success rate of JAK inhibitors in treating rheumatoid arthritis varies among individuals. Clinical studies have demonstrated that JAK inhibitors can reduce symptoms, improve joint function, and slow disease progression in many patients. However, individual responses may differ; some patients experience better outcomes. The success of JAK inhibitors also depends on factors such as disease severity, overall health, and treatment adherence. Close collaboration with a healthcare provider and regular monitoring can help optimize each patient's success rate of JAK inhibitors.
Various drugs have successfully treated rheumatoid arthritis, and the level of success can vary based on individual patient responses. Some of the most successful drugs for rheumatoid arthritis include DMARDs like methotrexate, biologic agents such as TNF inhibitors, and newer targeted therapies like JAK inhibitors. The effectiveness of these drugs is often evaluated based on their ability to alleviate symptoms, improve joint function, and slow disease progression. Choosing the most suitable drug depends on factors such as the patient's medical history, disease severity, and potential side effects, with treatment plans tailored to each individual's needs.
New treatment options for rheumatoid arthritis continue to emerge, including innovative biological therapies, targeted small molecules like JAK inhibitors, and personalized medicine approaches. These advancements aim to provide more effective symptom relief, improved joint function, and better patient outcomes. Research and clinical trials are ongoing to explore novel therapies that can address unmet needs and offer additional alternatives for managing rheumatoid arthritis. It's advisable to consult with a healthcare provider or rheumatologist for the most up-to-date information.
Source Article IclonSourcesSource Article Arrow
Dr. Mohammad Rajja from iCliniq
Dr. Mohammad Rajja

General Practitioner

Consult this doctor

Rate this article

Tags:

janus kinase inhibitorsrheumatoid arthritis

Related topics

Baricitinib - Dosages, Precautions and Side Effects

I have rheumatoid arthritis. How frequently do I need to consult my rheumatologist?

Physical Therapy in Rheumatoid Arthritis

I have rheumatoid arthritis with severe pain in joints. Kindly help.

Ask your health query to a doctor online

General Medicine

*guaranteed answer within 4 hours

Trustpilot

Disclaimer: No content published on this website is intended to be a substitute for professional medical diagnosis, advice or treatment by a trained physician. Seek advice from your physician or other qualified healthcare providers with questions you may have regarding your symptoms and medical condition for a complete medical diagnosis. Do not delay or disregard seeking professional medical advice because of something you have read on this website. Read our Editorial Process to know how we create content for health articles and queries.